ザナフレックスの薬剤に関する洞察と市場予測：2032年

ザナフレックス（チザニジン）は中枢性α2作動薬です。複数の疾患に対する抗痙縮薬として広く使用されています。

チザニジンは、イミダゾリン誘導体であり、中枢に作用するα2受容体作動薬です。脊髄介在ニューロンからのグルタミン酸やアスパラギン酸などの興奮性アミノ酸の放出を阻害します。その結果、チザニジンは運動ニューロンのシナプス前抑制を増強します。脊髄ポリシナプス経路に対して重要な作用を示します。

これらの作用の全体的な効果は、脊髄運動ニューロンの促進を減少させることです。同様に、α2受容体を介した神経細胞間活動の抑制も、チザニジンの抗侵害受容作用と抗けいれん作用の根底にあるようです。痙攣頻度とクローヌスもチザニジンによって減少します。

また、チザニジンはα1受容体にも親和性を示しますが、その程度は低いため、クロニジンとの構造的・生化学的類似性にもかかわらず、心血管系に対する作用が穏やかで一過性のものであることが説明できます。

今後数年間で、痙縮の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新しいアプローチに焦点を当てた治療法を開発し、課題を評価し、ザナフレックスの優位性に影響を与える可能性のある機会を模索しています。痙縮に対する他の新興製品は、ザナフレックスに厳しい市場競争をもたらすことが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるでしょう。

当レポートでは、主要7ヶ国におけるザナフレックス市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 痙縮に対するザナフレックスの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ザナフレックス市場評価

• 痙縮に対するザナフレックスの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における痙縮に対するザナフレックスの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ZANAFLEX, Clinical Trial Description, 2023
• Table 2: ZANAFLEX, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: ZANAFLEX Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ZANAFLEX Market Size in the US, in USD million (2019-2032)
• Table 7: ZANAFLEX Market Size in Germany, in USD million (2019-2032)
• Table 8: ZANAFLEX Market Size in France, in USD million (2019-2032)
• Table 9: ZANAFLEX Market Size in Italy, in USD million (2019-2032)
• Table 10: ZANAFLEX Market Size in Spain, in USD million (2019-2032)
• Table 11: ZANAFLEX Market Size in the UK, in USD million (2019-2032)
• Table 12: ZANAFLEX Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ZANAFLEX Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ZANAFLEX Market Size in the United States, USD million (2019-2032)
• Figure 3: ZANAFLEX Market Size in Germany, USD million (2019-2032)
• Figure 4: ZANAFLEX Market Size in France, USD million (2019-2032)
• Figure 5: ZANAFLEX Market Size in Italy, USD million (2019-2032)
• Figure 6: ZANAFLEX Market Size in Spain, USD million (2019-2032)
• Figure 7: ZANAFLEX Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ZANAFLEX Market Size in Japan, USD million (2019-2032)

“"ZANAFLEX Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ZANAFLEX for spasticity in the seven major markets. A detailed picture of the ZANAFLEX for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ZANAFLEX for spasticity. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZANAFLEX market forecast analysis for spasticity in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in spasticity.

Drug Summary:

ZANAFLEX (tizanidine) is a centrally acting alpha-2 agonist. It is widely used as an anti-spastic agent for multiple medical conditions.

Mechanism of action

Tizanidine is an imidazoline derivative and a centrally acting alpha-2 receptor agonist. Tizanidine inhibits the release of excitatory amino acids like glutamate and aspartate from spinal interneurons. Consequently, tizanidine enhances the presynaptic inhibition of motor neurons. Tizanidine has significant action on spinal polysynaptic pathways.

The overall effect of these actions is to reduce the facilitation of spinal motor neurons. Similarly, alpha-2 receptor-mediated inhibition of inter-neuronal activity appears to underlie tizanidine's additional anti-nociceptive and anti-convulsant activities. Spasm frequency and clonus are also reduced by tizanidine.

Tizanidine also has an affinity for the alpha-1 receptors but to a lesser degree, which may explain its mild and transitory effect on the cardiovascular system compared to clonidine despite their structural and biochemical similarity.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ZANAFLEX description, mechanism of action, dosage and administration, research and development activities in spasticity.
• Elaborated details on ZANAFLEX regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZANAFLEX research and development activities in spasticity across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ZANAFLEX.
• The report contains forecasted sales of ZANAFLEX for spasticity till 2032.
• Comprehensive coverage of the late-stage emerging therapies for spasticity.
• The report also features the SWOT analysis with analyst views for ZANAFLEX in spasticity.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZANAFLEX Analytical Perspective by DelveInsight

In-depth ZANAFLEX Market Assessment

This report provides a detailed market assessment of ZANAFLEX for spasticity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

ZANAFLEX Clinical Assessment

The report provides the clinical trials information of ZANAFLEX for spasticity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for spasticity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZANAFLEX dominance.
• Other emerging products for spasticity are expected to give tough market competition to ZANAFLEX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZANAFLEX in spasticity.
• Our in-depth analysis of the forecasted sales data of ZANAFLEX from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZANAFLEX in spasticity.

Key Questions:

• What is the product type, route of administration and mechanism of action of ZANAFLEX?
• What is the clinical trial status of the study related to ZANAFLEX in spasticity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZANAFLEX development?
• What are the key designations that have been granted to ZANAFLEX for spasticity?
• What is the forecasted market scenario of ZANAFLEX for spasticity?
• What are the forecasted sales of ZANAFLEX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZANAFLEX for spasticity?
• Which are the late-stage emerging therapies under development for the treatment of spasticity?

Table of Contents

1. Report Introduction

2. ZANAFLEX Overview in Spasticity

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ZANAFLEX Market Assessment

• 5.1. Market Outlook of ZANAFLEX in Spasticity
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ZANAFLEX in the 7MM for Spasticity
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ZANAFLEX in the United States for Spasticity
  • 5.3.2. Market Size of ZANAFLEX in Germany for Spasticity
  • 5.3.3. Market Size of ZANAFLEX in France for Spasticity
  • 5.3.4. Market Size of ZANAFLEX in Italy for Spasticity
  • 5.3.5. Market Size of ZANAFLEX in Spain for Spasticity
  • 5.3.6. Market Size of ZANAFLEX in the United Kingdom for Spasticity
  • 5.3.7. Market Size of ZANAFLEX in Japan for Spasticity

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options